Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of October 2022, with a specific report date of October 19, 2022. The filing serves to disseminate a press release regarding a regulatory milestone for the Company's ProSense® device.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material event reported is the submission of a De Novo Classification request to the U.S. Food and Drug Administration (FDA). This request seeks marketing authorization for the ProSense® device with a Breakthrough Indication specifically for early-stage, low-risk breast cancer patients who are at high risk for surgery.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statements" section of the accompanying press release (Exhibit 99.1). While the text confirms the existence of these statements, it does not reproduce the specific content regarding future guidance, detailed risks, or contingencies within the body of this Form 6-K.
Investor Verification Checklist
- Verify the specific clinical data supporting the Breakthrough Indication request in the full press release (Exhibit 99.1).
- Confirm the FDA's timeline for reviewing the De Novo Classification request.
- Review the incorporated Forward-Looking Statements for specific risks related to regulatory approval delays or rejection.
- Check subsequent filings for updates on the status of the ProSense® marketing authorization.